BV-AVD方案治疗非大包块局限期经典型霍奇金淋巴瘤
多中心2期研究评估维布妥昔单抗联合多柔比星、长春碱和达卡巴嗪(BV-AVD)治疗非大包块I/II期经典型霍奇金淋巴瘤,34例患者最佳完全缓解率100%,中位随访38个月无进展生存94%、总生存97%,但毒性高于AVD预期。
要点
- BV-AVD方案最佳完全缓解率达100%,中位随访38个月PFS 94%、OS 97%。
- 最常见不良事件为周围感觉神经病变79%、中性粒细胞减少76%、疲乏74%、恶心71%。
- 3/4级毒性以中性粒细胞减少62%、发热性中性粒细胞减少35%、周围感觉神经病变24%为主。
核心结论
- BV-AVD方案不含博来霉素和放疗,在非大包块I/II期经典型霍奇金淋巴瘤中产生高完全缓解率,多数患者仅需4个总周期治疗。
- 因毒性高于AVD单独预期,该方法可能不适用于预后高度良好的早期患者。
研究设计与样本
- 多中心2期研究,纳入34例非大包块I/II期经典型霍奇金淋巴瘤患者,中位年龄36岁(范围20-75岁)。
- 患者先接受1周期维布妥昔单抗单药(第1、15天),随后根据第2周期后中期PET/CT接受4至6周期BV-AVD治疗。
主要发现
- 最佳完全缓解率为100%。
- 中位随访38个月时,无进展生存率为94%,总生存率为97%。
- 最常见不良事件为周围感觉神经病变(79%)、中性粒细胞减少(76%)、疲乏(74%)和恶心(71%)。
- 最常见3/4级毒性为中性粒细胞减少(62%)、发热性中性粒细胞减少(35%)和周围感觉神经病变(24%)。
- 一例老年患者在首个BV-AVD周期死于中性粒细胞减少性脓毒症;38%患者需降低维布妥昔单抗剂量,多数因周围神经病变。
关键数值与推荐
- 风险分组:早期有利型62%,不利型38%。
- 治疗方案:维布妥昔单抗单药引导周期第1、15天,随后BV-AVD 4至6周期,依据第2周期后中期PET/CT决定周期数。
临床怎么用
- BV-AVD方案可使多数非大包块I/II期经典型霍奇金淋巴瘤患者仅需4个总周期治疗。
- 该方案毒性高于AVD单独预期,对预后高度良好的早期患者可能不适用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without radiation is standard therapy for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin-induced lung injury and radiation toxicity. Brentuximab vedotin is highly active in relapsed HL and was recently approved with doxorubicin, vinblastine, and dacarbazine (AVD) for previously untreated stage III/IV HL. We evaluated brentuximab-AVD for nonbulky stage I/II HL in a multicenter phase 2 study. Patients received a lead-in cycle of brentuximab vedotin monotherapy on days 1 and 15, followed by an exploratory positron emission tomography/computed tomography scan. Patients then received brentuximab-AVD for 4 to 6 cycles based on interim positron emission tomography/computed tomography scanning after cycle 2. Thirty-four patients were enrolled with a median age of 36 years (range, 20-75 years). Risk was early favorable in 62% and unfavorable in 38%. The best complete response rate was 100%. At a median follow-up of 38 months, the progression-free survival and overall survival were 94% and 97%, respectively. The most common adverse events were peripheral sensory neuropathy (79%), neutropenia (76%), fatigue (74%), and nausea (71%). The most common grade 3/4 toxicities were neutropenia (62%), febrile neutropenia (35%), and peripheral sensory neuropathy (24%). One elderly patient died of neutropenic sepsis in the first brentuximab-AVD cycle. Brentuximab dose reductions were required in 38% of patients, most for peripheral neuropathy. In conclusion, brentuximab-AVD without bleomycin or radiation produced a high complete response rate, with most patients requiring only 4 total cycles of therapy. Because toxicity was higher than would be expected from AVD alone, this method may not be appropriate for early-stage patients with a highly favorable prognosis. This trial was registered at www.clinicaltrials.gov as #NCT01534078.
引用
- Abramson JS, Arnason JE, LaCasce AS, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019. PMID: 31186274. doi:10.1182/blood.2019001272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。